Evidence map›Paper›PMID 35380688›Full record

ArticleMolecular cancer research : MCR2022

PDZ Proteins SCRIB and DLG1 Regulate Myeloma Cell Surface CD86 Expression, Growth, and Survival.

Tyler Moser-Katz, Catherine M Gavile, Benjamin G Barwick, Kelvin P Lee, Lawrence H Boise

Open access · greenAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Tyler Moser-KatzDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.
Catherine M GavileDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.
Benjamin G BarwickDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.ORCID 0000-0001-9810-3566
Kelvin P LeeMelvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana.
Lawrence H BoiseDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.ORCID 0000-0001-9436-8815
Emory University · USIndiana University Health · US

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
Training Program in Biochemistry, Cell and Molecular BiologyT32GM008367 · NIGMS · EMORY UNIVERSITY · PI BOISE, LAWRENCE H., CORBETT, ANITA H. · 1990 to 2019
$5.6M
CD28-mediated Regulation of Multiple Myeloma Cell Proliferation and SurvivalR01CA121044 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI LEE, KELVIN P. · 2007 to 2023
$4.8M
The Role of CD86 in Multiple MyelomaR01CA192844 · NCI · EMORY UNIVERSITY · PI BOISE, LAWRENCE H. · 2016 to 2020
$1.9M
NCI NIH HHS P30 CA138292NCI NIH HHS R01 CA121044NCI NIH HHS R01 CA192844NIGMS NIH HHS T32 GM008367
6 · The paper itself

Abstract

Despite advances in the treatment of multiple myeloma in the past decades, the disease remains incurable, and understanding signals and molecules that can control myeloma growth and survival are important for the development of novel therapeutic strategies. One such molecule, CD86, regulates multiple myeloma cell survival via its interaction with CD28 and signaling through its cytoplasmic tail. Although the CD86 cytoplasmic tail has been shown to be involved in drug resistance and can induce molecular changes in multiple myeloma cells, its function has been largely unexplored. Here, we show that CD86 cytoplasmic tail has a role in trafficking CD86 to the cell surface. This is due in part to a PDZ-binding motif at its C-terminus which is important for proper trafficking from the Golgi apparatus. BioID analysis revealed 10 PDZ domain-containing proteins proximal to CD86 cytoplasmic tail in myeloma cells. Among them, we found the planar cell polarity proteins, SCRIB and DLG1, are important for proper CD86 surface expression and the growth and survival of myeloma cells. These findings indicate a mechanism by which myeloma cells confer cellular survival and drug resistance and indicate a possible motif to target for therapeutic gain. IMPLICATIONS: These findings demonstrate the importance of proper trafficking of CD86 to the cell surface in myeloma cell survival and may provide a new therapeutic target in this disease.

Indexed as

B7-2 AntigenDiscs Large Homolog 1 ProteinMembrane ProteinsMultiple MyelomaTumor Suppressor ProteinsCD28 AntigensCell MembraneCell PolarityHumansPDZ DomainsTranscription FactorsB7-2 AntigenCD28 AntigensCD86 protein, humanDiscs Large Homolog 1 ProteinDLG1 protein, humanMembrane ProteinsSCRIB protein, humanTranscription FactorsTumor Suppressor Proteins

Identifiers

PMID35380688
PMCPMC9262820
OpenAlexW4226069917

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.